Impact of local anesthetics on epigenetics in cancer

Lucillia Bezu1,2,3*, Oliver Kepp1,2 and Guido Kroemer1,2,4*

1Equipe Labellisée Par La Ligue Contre Le Cancer, Université de Paris, Sorbonne Université, INSERM UMR1138, Centre de Recherche des Cordeliers, Institut Universitaire de France, Paris, France, 2Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, Université Paris Saclay, Villejuif, France, 3Service d’Anesthésie Gustave Roussy Cancer Campus, Villejuif, France, 4Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, Paris, France

Defective silencing of tumor suppressor genes through epigenetic alterations contributes to oncogenesis by perturbing cell cycle regulation, DNA repair or cell death mechanisms. Reversal of such epigenetic changes including DNA hypermethylation provides a promising anticancer strategy. Until now, the nucleoside derivatives 5-azacytidine and decitabine are the sole DNA methyltransferase (DNMT) inhibitors approved by the FDA for the treatment of specific hematological cancers. Nevertheless, due to their nucleoside structure, these inhibitors directly incorporate into DNA, which leads to severe side effects and compromises genomic stability. Much emphasis has been placed on the development of less toxic epigenetic modifiers. Recently, several preclinical studies demonstrated the potent epigenetic effects of local anesthetics, which are routinely used during primary tumor resection to relieve surgical pain. These non-nucleoside molecules inhibit DNMT activity, affect the expression of micro-RNAs and repress histone acetylation, thus exerting cytotoxic effects on malignant cells. The in-depth mechanistic comprehension of these epigenetic effects might promote the use of local anesthetics as anticancer drugs.

KEYWORDS
local anesthetics, epigenetic, cancer, demethylation, miRNA

Abbreviations: Ca++, calcium ion; DAC, dacogen (decitabine); DNMT, DNA methyltransferase; EGFR, Epithelial Growth Factor Receptor; EMA, European Medicines Agency; ERK, Extracellular signal-Regulated Kinases; FDA, Food and Drug Administration; 5-FU, 5 fluorouracil; IL, interleukin; LA, local anesthetics; mTOR, mammalian target of rapamycin; NK, natural killer cells; RARβ, retinoic acid receptor β; RASSF1A, Ras association domain family 1A.
Introduction

Epigenetic alterations and cancer

Epigenetic alterations are common molecular hallmarks of most cancers (1). In normal cells, epigenetic changes are fundamental for the control of gene expression, for the maintenance of cellular identities and for acquisition of an ever more differentiated and specialized phenotype (2). Epigenetic changes are highly regulated to maintain the stability of the epigenome and cellular homeostasis. However, aberrant patterns of DNA methylation, histone modifications (acetylation, methylation, phosphorylation, etc.) and dysregulation of non-coding RNAs correlate with the development of various kinds of cancers by inactivating tumor suppressor genes, by perturbing DNA repair and chromatin remodeling, or by promoting oncogenic pathways (2, 3). These modifications are under the control of interconnected regulators. For instance, many micro-RNAs (miRNAs) can stimulate cellular proliferation by directly interacting with cell-cycle components, as this has been reported for miR-17-92, miR-221/222, miR-663, miR-302 or miR-24, which target the transcription factor E2F1 or the cyclin dependent kinase (CDK) inhibitors p27Kip1, p21CIP1 and p16INK4a, respectively (4–8). The hypermethylation of DNA, which is associated with multiple pathologies, is characterized by the transfer of methyl groups to the position 5 of cytosine residues at CpG islands, which may be located in the promoter regions of tumor suppressive genes, thus inducing their inactivation (9). This reaction is catalyzed by a family of DNA methyltransferases encoded by four specific genes (DNMT1, DNMT2, DNMT3a and DNMT3b) that synergistically promote oncogenesis (9–11). Of note, hypermethylation of DNA is perfectly reversible, and silent genes can be reactivated by administration of hypomethylating agents. Two demethylating drugs were approved by the FDA for this purpose: 5-azacytidine and the cytidine analog 5-aza-2'-deoxycytidine also known as decitabine (sold under the brand name dacogen, DAC). After their incorporation into genomic DNA, both agents directly inhibit DNMTs. In the clinic, they are exclusively prescribed for the treatment of myelodysplasia and acute myeloid leukemia (12). However, despite promising preliminary preclinical data (such as the promotion of cancer cell apoptosis in vitro and the reduction of tumor growth in mouse models), 5-azacytidine and decitabine provoke considerable side-effects in patients (e.g. mutagenicity, thrombocytopenia and prolonged neutropenia), limiting their employment and motivating their continuous investigation in clinical trials (13). For this reason, the search for ever less toxic hypomethylating agents is ongoing.

Recently, local anesthetics (LA) such as bupivacaine, levobupivacaine, lidocaine, ropivacaine and procaine were described to act as non-nucleoside DNA demethylating agents responsible for upregulating transcriptionally silent genes (14–21), to interfere with the expression of several miRNAs and to impact on the level of histone acetylation (22). These LA are currently employed for their analgesic and anti-inflammatory properties, but also turned out to be endowed with potent antitumor effects (23–33).

Local anesthetics induce antitumor effects

LA are commonly used during oncological surgery to relieve the acute pain generated by the surgical procedure. Several retrospective clinical trials reported a notable improvement of overall survival and a reduction in recurrence after primary tumor resection under local anesthesia compared to general anesthesia alone (23, 26, 34–36). This epidemiological evidence suggests that LA might have antitumor effects. Several pathways that may explain such antineoplastic effects have been described in the literature. Indeed, preclinical data indicate that LA influence the migration and the survival of cancer cells. At clinically relevant concentrations, LA inhibit the proliferation of cancer cells by provoking cell cycle arrest, by triggering mitochondrial dysfunction or by causing apoptotic cell death (28, 29, 37). Moreover, LA abrogate the migration of cancer cells after inducing intracellular Ca2+ changes that affect the cytoskeleton (24). LA also inhibit the secretion of matrix metalloproteinases necessary for the invasion of cancer cells into the extracellular matrix (38). The anti-inflammatory property of LA reduces the levels of procarcinogenic cytokine interleukin-6 (IL-6) detectable in the serum of patients during oncological surgery (25, 39). In vivo, LA elicit an antitumor immune response, thus causing tumor growth reduction in mice and extending the lifespan of animals with solid tumors (20, 40). When combined with chemotherapeutic agents such as 5-fluorouracil, paclitaxel or platinum salts, LA induce a synergistic antitumor effect, meaning that they sensitize cancer cells to the cytotoxicity of chemotherapy (14, 41). Taken together, the current state of the literature supports the contention that LA may directly kill cancer cells and also promote immune responses against neoplastic cells.

Hitherto, only few prospective trials investigated the role of local anesthetics on oncological prognosis (42). Most studies failed to support a direct impact on clinical outcome. However, the continued accumulation of irrefutable preclinical data demonstrating antitumor effects of local anesthetics encourages clinicians to further pursue investigations as illustrated by several randomized controlled trials recorded at www.clinicaltrials.gov and summarized in (43). Among the published scientific readouts, it can be suspected that at least some of these effects are secondary to LA effects on the tumor epigenome. Here, we summarize preclinical data highlighting
the epigenetic mode of action through which LA could exert their antineoplastic activity.

Local anesthetics promote DNA demethylation and restore expression of tumor suppressor genes

Several studies observed that aminoamide-type local anesthetics such as bupivacaine, lidocaine, ropivacaine and ester-type local anesthetic like procaine mediate antitumor effects as well as global DNA demethylation in many types of solid cancers in a time-and dose-dependent manner (Table 1). For instance, bupivacaine, lidocaine and ropivacaine turned out to be potent DNA-demethylating agents of RASSF1A, hampering the proliferation of human hepatocarcinoma HepG2 and BEL-7402 cells (45). Lidocaine triggered apoptosis of human breast cancer BT-20 and MCF-7 cells by inducing the expression of the tumor suppressive RARβ2 and RASSF1A genes (14). Procaine reduced global DNA methylation by 40% in breast cancer MCF-7 cells by inhibiting DNMT1 (21) and showed an outstanding ability to minimize the growth, the proliferation and the invasion of various human cancers both in vitro and in vivo (15, 17, 20, 21). Interestingly, LA can sterically inhibit DNMT binding to CpG islands or to DNA (15, 21, 47) (Figure 1). As a consequence, the epigenetic regulation by LA could represent a therapeutic option. Indeed, the cytotoxic effects of conventional chemotherapeutic agents such as cisplatin or carboplatin are significantly potentiated when they are combined with LA (14, 17, 45). The association of both lidocaine and cisplatin triggers a higher level of cancer cell apoptosis than lidocaine or cisplatin alone because of the re-expression of the RASSF1A and RARβ2 genes (14). Combined with 5-aza-2′-deoxycytidine, an interesting additive demethylating effect was observed for lidocaine (44).

The effects induced by LA-mediated epigenetic modulation are not limited to the restoration of tumor suppressor gene expression but also modulate the sensitivity to pain (48) and influence the response to corticoid stress during surgery (49, 50), altogether profoundly impinging on the activity of anti-tumor effectors (49, 51). Until now, opioids have been the most commonly used analgesics for controlling acute pain. However, preclinical data indicate that opioids mediate pro-tumorigenic effects via the activation of matrix metalloproteinases and oncogenes like c-Myc as well as via an increase in DNA methylation (52–54). Of note, DNA methylation leads to the expression of the mu opioid receptor and predicts the response to endogenous endorphins and opioid analogues (55). Paradoxically,

| Agents | Cancer | Human cell lines | Epigenetic changes | Anticancer effects | Ref |
|--------|--------|------------------|--------------------|--------------------|-----|
| Lidocaine | Breast | BT-20 | Global DNA demethylation | Apoptosis | (44) |
| Ropivacaine | Breast | BT-20 | Global DNA demethylation | | |
| | | MCF-7 | | | |
| | | MDA-MB-231 | | | |
| Lidocaine | Liver | HepG2 | Demethylation of tumor suppressor genes RASSF1A (restoration of expression) | | |
| Ropivacaine | Liver | BEL-7402 | | | |
| Bupivacaine | Breast | MCF-7 | Global DNA demethylation by inhibiting DNMT1 | Growth inhibition | (21) |
| Procaine | Breast | HLE | Global DNA demethylation and 5-aza-2′-deoxycytidine induce additive demethylating effect | | |
| Procaine | Colon | HCT116 | Procaine alone (3μM) or combined with carboplatin (3μM) induce demethylation | Reduced viability | (17) |
| Procaine | Gastric | SGC-7901 | Global DNA demethylation by repressing DNMT1 and DNMT3a activity | | |
| Procaine | Lung | H460 | Demethylation of WIF-1 (restoration of expression) | | |

DNMT, DNA methyltransferase; RARβ, retinoic acid receptor β; RASSF1A, Ras Association Domain Family 1A.
excessive administration of opioids increases the risk of hyperalgesia during the postoperative period. It is tempting to speculate that the epigenetic demethylating activity of LA could prevent the hyperalgesia induced by both hypermethylation and opioids and hence counteract the opioid-mediated protumoral effects as well. Thus, opioid-free anesthesia, in which opioids are replaced by a mix of local anesthetics and other analgesic agents, offers a possibility to relieve pain, and to alleviate surgical stress-induced epigenetic changes, thereby restoring the expression of tumor suppressor genes.

Local anesthetics regulate non-coding RNAs

MiRNAs belong to the family of non-coding RNAs. Their main role is to control gene expression at different levels, and their dysregulation may trigger malignant transformation (56). LA are endowed with the capacity to enhance or suppress the expression of a variety of miRNAs, which differ according to the employed molecules and cancer cell lines (Table 2). The regulation of miRNAs by LA impacts several signaling pathways that mediate oncogenesis. Most of these pathways repress the downstream signaling pathway mediated by protein kinase B (PKB, best known as AKT) and mammalian target of rapamycin (mTOR), thus deeply affecting the proliferation, migration and invasion of cancer cells and inducing apoptosis (Figures 1, 2) (81). Interestingly, mTOR was described as a major regulator of energy metabolism by controlling oxidative phosphorylation (84). LA are known to induce mitochondrial dysfunction leading to the production of reactive oxygen species. Indeed, the antitumor activity of ropivacaine involves both the disruption of mitochondrial function and the inhibition of Akt and mTOR phosphorylation, highlighting a putative link between AKT/mTOR and mitochondrial activity in cancer (85). Moreover, the inhibition of the AKT-mTOR pathway by LA demonstrated a relevant impact in preclinical experiments. Indeed, lidocaine-promoted miRNA regulation reversed cisplatin-resistance in MGC-803/DDP gastric cells, minimized the cisplatin resistance in lung cancer cells A549/DDP and increased the cytotoxicity of 5-fluorouracil against SK-MEL-2 melanoma cells via upregulation of miR-493 (67, 72, 74). LA also exert antineoplastic properties by acting on the epithelial growth factor receptor (EGFR) axis. For instance, lidocaine inhibits the proliferation of lung cancer cells via upregulation of miR-539, which directly targets EGFR (71). Lidocaine also minimizes the progression of retinoblastoma both in vitro and in vivo by downregulating EGFR expression through the upregulation of miR-520a-3p (77).

The extracellular signal-regulated kinases (ERK) signaling pathway is also impacted by the modulation of miRNA expression induced by LA. In a model of osteosarcoma, procaine significantly blocked the proliferation and migration of tumor cells and promoted apoptosis by upregulating miR-133b. In parallel, the level of p/ERK was profoundly decreased. The employment of miR-133b inhibitors reversed all the observed effects including the phosphorylation of ERK, revealing the interaction between this pathway and non-coding RNAs (31). Interestingly, the regulation of miRNAs by LA can target several pathways, thus inducing synergistic effect. Thus, lidocaine can upregulate the expression of miR-145b,
| Agents          | Cancer          | Human cell lines | Epigenetic changes | Target                     | Anticancer effects                              | Ref   |
|-----------------|-----------------|------------------|--------------------|----------------------------|------------------------------------------------|-------|
| Bupivacaine     | Neuroblastoma   | SH-SY5Y          | miR-132 upregulation | IGFR1                      | Proliferation inhibition                         | (57)  |
|                 |                 |                  |                    | Decrease in p-Akt           | Apoptosis                                       |       |
|                 |                 |                  |                    | miR-421 downregulation      | Apoptosis                                       | (58)  |
|                 |                 |                  |                    | ZNF564 upregulation         |                                                 |       |
| Bupivacaine     | Neuroblastoma   | SH-SY5Y          | IncRNA ZFAS1 upregulation | miR-101-3-3p downregulation | Apoptosis                                       | (59)  |
|                 |                 |                  |                    | PDCD4 upregulation          |                                                 |       |
| Bupivacaine     | Neuroblastoma   | SH-SY5Y          | LINC00665 downregulation | hsa-miR-34a-5p              | Apoptosis                                       | (60)  |
| Bupivacaine     | Gastric         | AGS HGC27        | miR-145-5p upregulation | Decrease in Circ_0000376    | Migration and invasion inhibition, Glycolysis inhibition | (61)  |
|                 |                 |                  |                    |                            | Apoptosis                                       |       |
| Bupivacaine     | Breast          | MCF-7            | miR-187-5p upregulation | IncRNA DANC1 and MYB        | Inhibition of migration Apoptosis                | (62)  |
|                 |                 |                  |                    | downregulation             |                                                 |       |
| Levobupivacaine | Gastric         | HGC27 SGC7901    | miR-489-3p upregulation | SLC7A11                    | Growth inhibition, Ferroptosis                   | (63)  |
| Lidoceaine      | Breast          | MCF-7            | miR-187-5p upregulation | IncRNA DANC1 and MYB        | Migration inhibition Apoptosis                   | (62)  |
|                 |                 |                  |                    | downregulation             |                                                 |       |
| Lidoceaine      | Cervix          | HeLa             | IncRNA-MEG3 upregulation | miR-421 downregulation     | Proliferation inhibition Apoptosis               | (64)  |
|                 |                 |                  |                    | BTG1 upregulation           |                                                 |       |
| Lidoceaine      | Colon Rectum    | SW480 HCT116 NCM460 | miR-520a-3p upregulation | miR-1204 downregulation    | Proliferation inhibition Apoptosis               | (65)  |
|                 |                 |                  |                    | SOCS2 upregulation          |                                                 |       |
| Lidoceaine      | Colon Rectum    | SW620 LeVo       | CircTTF2 upregulation  | miR-21-5p downregulation   | Migration and invasion inhibition Apoptosis      | (66)  |
|                 |                 |                  |                    |                            |                                                 |       |
| Lidoceaine      | Gastric         | MGC-803 MGC-803/DDP | miR10b downregulation | AKT/mTOR inhibition        | Migration and invasion inhibition, Glioblastoma resistance reduction | (67)  |
| Lidoceaine      | Gastric         | GES-1 AGS HGC-27 | Circ_ANOS upregulation | miR-21-5p downregulation   | Proliferation, migration and invasion inhibition | (68)  |
|                 |                 |                  |                    | LIFR upregulation           | Tumor growth inhibition Apoptosis                |       |
| Lidoceaine      | Gastric         | MKN45            | miR-145 upregulation  | MEK/ERK and NF-xB Inactivation | Growth, migration and invasion inhibition Apoptosis | (18)  |
| Lidoceaine      | Glioma          | U-251MG T98G     | CircEZH2 downregulation | miR-181b-5p upregulation   | Proliferation, migration and invasion inhibition | (69)  |
|                 |                 |                  |                    |                            | Apoptosis                                       |       |
| Lidoceaine      | Liver           | Huh7 Hep3B       | CircITCH upregulation  | miR-421 downregulation     | Proliferation, migration and invasion inhibition | (70)  |
|                 |                 |                  |                    | CPEB3 upregulation          | Apoptosis                                       |       |
| Lidoceaine      | Lung            | A549 NCI-H1299   | miR-539 upregulation  | EGFR inhibition            | Migration and invasion inhibition Apoptosis      | (71)  |
|                 |                 |                  |                    |                            |                                                 |       |
| Lidoceaine      | Lung            | A549 A549/DDP    | miR-21 downregulation  | PTEN/PI3K/PIK3CA           | Migration and invasion inhibition Apoptosis      | (72)  |
|                 |                 |                  |                    | PDCD4/INK                   |                                                 |       |
| Lidoceaine      | Lung            | A549 PC9         | Circ_PDZD8 downregulation | miR-516b-5p upregulation  | Apoptosis                                       | (73)  |
|                 |                 |                  |                    | GOLT1A downregulation       |                                                 |       |
| Lidoceaine      | Melanoma        | SK-MEL-2         | miR-493 upregulation  | Sox4 downregulation        | Apoptosis, 5-FU cytotoxicity increase           | (74)  |
|                 |                 |                  |                    | Decrease in p-PI3K, p-AKT, p- |                                                 |       |
|                 |                 |                  |                    | Smad2                      |                                                 |       |
| Lidoceaine      | Neuroblastoma   | SH-SY5Y          | miR-145 upregulation  | PI3K/PIK3CA/mTOR inhibition | Growth inhibition, Autophagy                     | (75)  |
|                 |                 |                  |                    |                            |                                                 |       |
| Lidoceaine      | Neuroblastoma   | SH-SY5Y          | LINC01347 downregulation | hsa-miR-145-5p upregulation | Apoptosis                                       | (76)  |

(Continued)
which simultaneously inactivates both ERK and NF-κB pathways, potentiating the inhibition of proliferation, migration and invasion of malignant gastric cells (18).

Interestingly, different modalities of cell death triggered by epigenetic modulation were observed after LA treatment. The upregulation of miR-145 by lidocaine promoted autophagic flux in neuroblastoma SH-SY5Y cells (75). Lidocaine and levobupivacaine both induced ferroptosis by upregulating miR-382-5p and miR-489-3p, respectively (19, 63). The impact of LA on cellular stress and death pathways via the control of non-coding RNA emphasizes the possibility to use LA as novel antineoplastic therapeutics.

Finally, several reports suggest an intertwined regulation of multiple non-coding RNAs by LA. Indeed, lncRNAs and circular RNAs (circRNAs), a group of non-coding RNAs described to be involved in oncogenesis, may act as miRNA sponges. In a model of glioma, the treatment with ropivacaine suppressed tumor progression by upregulating the circRNA circSCAF11, while downregulating miR-145-5p (30). Inversely, bupivacaine decreased the expression of circ_0000376 while enhancing miR-145-5p in gastric cancer cells (61). Lidocaine hampered the proliferation of colorectal cancer cells by upregulating circTFG2 and then decreasing miR-1204 (66). In a model of gastric cancer, lidocaine hindered tumor progression by modifying the expression of various long non-coding RNAs (ZFAS1, MALAT1, LINC00665, which sponged

| Agents  | Cancer | Human cell lines | Epigenetic changes | Target | Anticancer effects | Ref |
|---------|--------|------------------|-------------------|--------|--------------------|-----|
| Lidocaine | Ovary  | SKOV-3 T47D      | miR-382-5p upregulation | SLC7A11 downregulation | Proliferation, migration and invasion inhibition, Tumor growth inhibition, Reactive Oxygen Species production, Ferroptosis | (19) |
| Lidocaine | Retinoblastoma | Y79 WERI-RB1 SO-BB50 SO-RB70 | miR-520a-3p upregulation | EGFR inhibition | Proliferation inhibition, Apoptosis | (77) |
| Lidocaine | Skin | A431 | miR-30c upregulation | SIRT1 downregulation | Proliferation inhibition, Inhibition of cisplatin resistance | (6) |
| Procaine | Osteosarcoma | MG63 | miR-133b upregulation | Decrease in p/t-AKT, p/t-ERK, and p/t-S6 | Proliferation and migration inhibition, Apoptosis | (31) |
| Ropivacaine | Breast | MCF-7 MDA-MB-231 | miR-27b-3p upregulation | YAP downregulation | Proliferation, migration and invasion inhibition, Tumor growth inhibition, Apoptosis | (78) |
| Ropivacaine | Cervix | Siha Caski | miR-96 downregulation | MEG2 upregulation | Growth inhibition, Apoptosis | (79) |
| Ropivacaine | Choriocarcinoma | NA | LNC0GFRP1 downregulation | miR-4731-5p upregulation HIF3A downregulation | Viability, migration and invasion inhibition, Apoptosis | (80) |
| Ropivacaine | Gastric | AGS BGC-823 | miR-520a-3p upregulation | PI3K/AKT inhibition | Proliferation, migration and invasion inhibition, Apoptosis | (81) |
| Ropivacaine | Glioma | T98G LN229 | circSCAF11 downregulation | miR-145-5p upregulation | Proliferation, migration and invasion inhibition, Tumor growth inhibition, Reactive Oxygen Species Apoptosis | (30) |
| Ropivacaine | Glioma | T98G LN229 | SNHG16 downregulation | miR-424-5 upregulation | Proliferation, migration and invasion inhibition, Apoptosis | (82) |
| Ropivacaine | Glioma | U87 U373 U251 | miR-21-5p upregulation | KANSL2 downregulation | Proliferation, migration and invasion inhibition, Apoptosis | (83) |
FIGURE 2
Local anesthetics inhibit cell proliferation, migration and invasion and promote cancer cell death via inhibition of several signaling pathways. Akt, protein kinase B; BTG1, B cell translocation gene 1; DDP, cisplatin; EGFR, Epithelial growth factor receptor; ERK, extracellular signal-regulated kinase; mTOR, mammalian Target of Rapamycin; PI3K, phosphoinositide-3 kinase; PTEN, Phosphatase and TENsin homolog; SOX4, SRY-Box Transcription Factor 4.
protumorigenic miR-421, miR-101-3-3p and miR-34a-5p, respectively) (58–60).

Local anesthetics repress histone acetylation in cancer cells

Previous publications reported that levobupivacaine, an amino amide LA widely used to control acute surgical pain, possesses the capacity to attenuate the oncological properties of several cancer types (86, 87). However, the mechanisms by which levobupivacaine exerts its anticancer activity remain poorly characterized. Lysine acetyltransferase 5 (KAT5) acetylates both non-histone and histone proteins and increases the invasiveness of cancer cells (88). Levobupivacaine inhibits the expression of KAT5 in osteosarcoma cells, thus inhibiting their proliferation and limiting their survival (22). This preclinical finding demonstrated the implication of LA in epigenetic changes on histones leading to anticancer properties. Interestingly, the inhibition of histone acetyltransferase activity decreases opioid-induced hyperalgesia in mice (89). Nevertheless, the impact of LA on histone modification as well as the oncological consequences remain unclear, calling for future exploration.

Discussion

The reversal of cancer-associated epigenetic dysregulations represents one possible antineoplastic strategy. Various demethylating molecules were characterized at the preclinical level (as exemplified by curcumin, (−)−epigallocatechin-3-gallate, N-phthalyl-tryptophan and zebularine) (90–94), and two agents (5-azacytidine and decitabine) have been approved by the FDA and EMA to treat patients with myelodysplastic syndrome or acute myeloid leukemia. These agents inhibit DNMT and hence reduce the global DNA methylation level in cancer cells. Despite their established anti-tumor activity, 5-azacytidine and decitabine induce severe myelosuppression, thus calling for the identification of novel epigenetic modulators.

Surprisingly, LA mediate significant antineoplastic activities by directly killing cancer cells and indirectly by eliciting antitumor immune responses (27, 32, 33, 37, 79, 95, 96). The detailed molecular comprehension of these effects may open a novel era in onco-anesthesia. Notably, the discovery of LA-promoted antitumor effects involving the induction of apoptosis secondary to the reduction of DNA methylation or the modulation of miRNAs has spurred much interest (18, 20, 30, 31, 67). Both amide and ester-type local anesthetics reduce global methylation levels in the promoter regions of tumor suppressor genes as a result of the inhibited interaction of DNMT with DNA. However, most preclinical studies have not yet investigated the effects of LA on the methylation of promoters of specific tumor suppressor genes as well as on the mRNA expression of such genes.

Beyond their effects on DNA methylation, LA also modulate (enhance or reduce) the expression of miRNAs in cancer cells, as summarized in a previous review (97). Compared to this published work, our review is the first one to critically evaluate all epigenetic changes induced by LA, including demethylating effects as well as miRNA regulation and histone acetylation, and to discuss their putative synergistic interaction with 5-azacytidine, decitabine and cytotoxicants. We surmise that the epigenetic effects of LA could be clinically relevant. Indeed, LA are well-known analgesics with a favorable toxicological profile that are commonly used during onco-rectal intervention. A positive clinical impact of LA on cancer recurrence would provide a low-risk and low-cost benefit to oncological patients. However, before such a conclusion can be reached, further clinical and translational research must confirm the capacity of LA to improve the outcome of surgical procedures, especially if they are preceded or followed by (neo)adjuvant chemotherapy or immunotherapy. It will be particularly important to investigate the short-term (intra-operational) and long-term (post-operational) effects of LA on epigenetic signatures including DNA methylation patterns and the expression of non-coding RNAs in further translational studies.

Author contributions

LB, OK and GK wrote the manuscript. All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.

Funding

OK is supported by Institut National du Cancer (INCa) and the DIM Elicit of the Ile-de-France. LB received a research grant by Bristol Myers Squibb Foundation France. GK is supported by the Ligue contre le Cancer (équipe labellisée); Agence National de la Recherche (ANR) – Projets blancs; AMMICa US23/CNRS UMS3655; Association pour la recherche sur le cancer (ARC); Association “Ruban Rose”; Cancéropôle Ile-de-France; Fondation pour la Recherche Médicale (FRM); a donation by Elior; Equipex Onco-Pheno-Screen; European Joint Programme on Rare Diseases (EJPRD); Gustave Roussy Odyssea, the European Union Horizon 2020 Projects Oncobiome and Crimson; Fondation Carrefour; INCa; Inserm (HTE); Institut Universitaire de France; LabEx Immuno-Oncology (ANR-18-IDEX-0001); the Leducq Foundation; a Cancer Research ASPIRE Award from the Mark Foundation; the RHU Torino Lumière; Seerave Foundation; SIRIC Stratified Oncology Cell
DNA Repair and Tumor Immune Elimination (SOCRATE); and SRIC Cancer Research and Personalized Medicine (CARPEM). This study contributes to the IdEx Université de Paris ANR-18-IDEX-0001.

Acknowledgments

The authors are grateful to the support of Gustave Roussy Cancer Campus, Université Paris-Saclay.

Conflict of interest

OK is scientific co-founder of Samsara Therapeutics. GK has been holding research contracts with Daichi Sankyo, Eleor, Kaleido, Lytix Pharma, Osasuna, PharmaMar, Samsara, Sanofi, Sotio, Vascage and Vascalox/Tioma. GK is on the Board of Directors of the Bristol Myers Squibb Foundation France. GK is a scientific co-founder of everImmune, Osasuna Therapeutics, Samsara Therapeutics and Therafast Bio. GK is the inventor of patents covering therapeutic targeting of aging, cancer, cystic fibrosis and metabolic disorders.

The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. Deltour S, Chopin V, Leprince D. Epigenetics and cancer. Medicine Sci M/S (2005) 21(4):405–11. doi: 10.1051/medsci/2005214405
2. Esteller M. Relevance of DNA methylation in the management of cancer. Lancet Oncol (2003) 4(6):531–8. doi: 10.1016/s1470-2045(03)01115-x
3. Bezu L, Chuang AW, Liu P, Kroemer G, Kepp O. Immunological effects of epigenetic modifiers. Cancer (2019) 11(12):1–20. doi: 10.3390/cancers11121951
4. Liu X, Zhao S, Sui H, Liu H, Yan M, Su Y, et al. MicroRNAs/LncRNAs modulate MDSCs in tumor microenvironment. Front Oncol (2022) 12:772351. doi: 10.3389/fonc.2022.772351
5. Liu QW, He Y, Xu WW. Molecular functions and therapeutic applications of exosomal noncoding RNAs in cancer. Exp Mol Med (2022) 54:216–25. doi: 10.1038/s12276-022-00744-w
6. Liu T, Jiang F, Yu LY, Wu YY. Lidocaine represses proliferation and cisplatin resistance in cutaneous squamous cell carcinoma via miR-30-5p/SIRT1 regulation. Bioengineered. (2022) 13(3):6359–70. doi: 10.1080/21655979.2022.2031419
7. Lal A, Kim HH, Abdelmohsen K, Kuwano Y, Pullmann R Jr., Srikantan S, et al. p16(INK4a) translation suppressed by miR-24. PloS One (2008) 3(3):e1864. doi: 10.1371/journal.pone.0001864
8. He L, Thomson JM, Hemann MT, Hernandez-Monge E, Mu D, Goodson S, et al. A microRNA polycistron as a potential human oncomiR. Nature. (2005) 435(7043):828–33. doi: 10.1038/nature03552
9. Klose RJ, Bird AP. Genomic DNA methylation: the mark and its mediators. Trends Biochem Sci (2006) 31(2):89–97. doi: 10.1016/j.tibio.2005.12.008
10. Okano M, Bell DW, Haber DA, Li E. DNA Methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell. (1999) 99(3):247–57. doi: 10.1016/s0092-8674(00)81656-6
11. Goll MG, Bestor TH. Eukaryotic cytosine methyltransferases. Annu Rev Biochem (2005) 74:481–514. doi: 10.1146/annurev.biochem.74.010904.153721
12. Ruter B, Wijermans PW, Lubbert M. DNA Methylation as a therapeutic target in hematologic disorders recent results in older patients with myelodysplasia and acute myeloid leukemia. Int J Hematol. (2004) 80(2):128–35. doi: 10.1533/ijcn.04.04094
13. Jabbour E, Issa JP, Garcia-Manero G, Kantarjian H. Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies. Cancer. (2008) 112(11):2341–51. doi: 10.1002/cncr.23543
14. Li K, Yang J, Han X. Lidocaine sensitizes the cytotoxicity of cisplatin in breast cancer cells via up-regulation of RARbeta2 and RASSF1A demethylation. Int J Mol Sci (2014) 15(12):23519–36. doi: 10.3390/ijms151223519
15. Li YC, Wang Y, Li DD, Zhang Y, Zhao TC, Li CF. Procaine is a specific DNA methylation inhibitor with anti-tumor effect for human gastric cancer. J Cell Biochem (2018) 119(2):2440–9. doi: 10.1002/jcb.26407
16. Lirk P, Berger R, Hollmann MW, Fleig H. Lidocaine time- and dose-dependently demethylates deoxycytidinonic acid in breast cancer cell lines in vitro. Br J anesthesia. (2012) 109(2):200–7. doi: 10.1093/bja/aes128
17. Sahit H, Samy MB, Said OA, El-Zawahri MM. Procaine induces epigenetic changes in HCT116 colon cancer cells. Genet Res Int (2016) 2016:8348450. doi: 10.1155/2016/8348450
18. Sui H, Lou A, Li Z, Yang J. Lidocaine inhibits growth, migration and invasion of gastric carcinoma cells by up-regulation of miR-145. BMC cancer. (2019) 19(1):233. doi: 10.1186/s12885-019-5431-9
19. Sun D, Li YC, Zhang XY. Lidocaine promoted ferroptosis by targeting miR-382–5p/LC7A11 axis in ovarian and breast cancer. Front Pharmacol (2021) 12:681223. doi: 10.3389/fphar.2021.681223
20. Tada M, Imaezi F, Fukai K, Sakamoto A, Arai M, Mikata R, et al. Procaine inhibits the proliferation and DNA methylation in human hepatoma cells. Hepatol Int (2007) 11(3):355–64. doi: 10.1111/j.1750-293X.2007.00014.x
21. Villar-Garea A, Fraga MF, Espada J, Esteller M. Procaine is a DNA-demethylating agent with growth-inhibitory effects in human cancer cells. Cancer Res (2005) 65(16):4984–9
22. Wang Z, Song Y, Zhang H, Yang Y, Zhang S, Wang W. Local anesthetic levobupivacaine inhibits stemness of osteosarcoma cells by epigenetically repressing MAFB though reducing KATS expression. Aging. (2022) 14(6):2793–804. doi: 10.18632/aging.203975
23. Biki B, Mascha E, Moriarty DC, Fitzpatrick JM, Sessler DI, Buggy DJ. Anesthetic technique for radical prostatectomy surgery affects cancer recurrence: a retrospective analysis. Anesthesiology. (2008) 109(2):180–7. doi: 10.1097/ALN.0b013e318175f37
24. D’Agostino G, Saporito A, Cecchinato V, Silvestri Y, Borget A, Anselmi L, et al. Lidocaine inhibits cytoskeletal remodelling and human breast cancer cell migration. Br J anesthesia. (2018) 121(4):962–8. doi: 10.1096/bja.2018.07.015
Anesthetic technique and the cytokine and matrix metalloproteinase response to primary breast cancer surgery. *Regional Anesth Pain Med* (2010) 35(6):490-5. doi: 10.1097/AAP.0b013e3181e4f8d0

Hiller JG, Hacking MB, Link EK, Wessels KL, Rieder B. Perioperative epidural analgesia reduces cancer recurrence after gastro-esophageal surgery. *Acta anaesthesiologica Scandinavica*. (2016) 58(3):281–90. doi: 10.1111/aas.12255

Jiang Y, Lou H, Zuo J, Tian S, Yu L. Lidocaine inhibits the invasion and migration of TRPV6-expressing cancer cells by TRPV6 downregulation. *Oncol Letters*. (2016) 12(2):1164-70. doi: 10.3892/ol.2016.4709

Lou J, Xu S, Zhang QQ, Xu R, Lei HY. Bupivacaine induces apoptosis via mitochondria and p38 MAPK dependent pathways. *Eur J Pharmacol*. (2011) 6571-3:51-8. doi: 10.1016/j.ejphar.2011.01.055

Wang W, Zhu M, Xu Z, Li W, Dong X, Chen Y, et al. Ropivacaine promotes apoptosis of hepatocellular carcinoma cells through damaging mitochondria and activating caspase-3 activity. *Biol Res*. (2019) 52(1):36. doi: 10.1186/s40609-019-0242-7

Yin D, Liu L, Shi Z, Zhang L, Yang Y. Ropivacaine induces cell proliferation, migration and invasion, whereas induces oxidative stress and cell apoptosis by circCAFI1/miR-145-5p axis in glioma. *Cancer Manage Res*. (2020) 12:11455-5. doi: 10.21473/CMAR.527497

Ying B, Huang H, Li H, Song M, Wu S, Ying H. Procarcin inhibits proliferation and migration and promotes cell apoptosis in osteosarcoma cells by upregulating Nrf2. *Oncol Res*. (2019) 27(9):1463-70. doi: 10.3277/00000542-2019-00097-4

Schlangenbaur B, Elbewanger U, Breuninger H, Stroebel W, Rassner G, Garbe C. Prognostic impact of the type of anesthesia used during the excision of primary cutaneous melanoma. *Melanoma Res* (2000) 10(2):165-9. doi: 10.1097/00008390-200004000-00009

Weng M, Chen W, Hou W, Li L, Ding M, Mao C. The effect of neuraxial anesthesia on cancer recurrence and survival after cancer surgery: an updated meta-analysis. *Oncotarget*. (2016) 7(12):15262-73. doi: 10.18632/oncotarget.7683

Chen J, Jiao Z, Wang A, Zhong W. Lidocaine inhibits melanoma cell proliferation by regulating ERK phosphorylation. *J Cell Biochem* (2019) 120(4):6402-8. doi: 10.1002/jcb.29727

Piegl T, Slapfer M, Dall RO, Schwartz DE, Borgeat A, Minshall RD, et al. Clinically relevant concentrations of lidocaine and ropivacaine inhibit TNFalpha-induced invasion of lung adenocarcinoma cells via activation of akt and focal adhesion kinase. *Bioengineered*. (2015) 6(5):784-9. doi: 10.1080/20435882.2015.1053439

Kuo CP, Jao SW, Chen KM, Wong CS, Yeh CC, Shen MJ, et al. Comparison of the effects of thoracic epidural analgesia and i.v. infusion with lidocaine on cytokine response, postoperative pain and bowel function in patients undergoing colonic surgery. *Br J Anaesthesia*. (2006) 97(5):640-6. doi: 10.1093/bja/ael217

Xing W, Chen DT, Pan JH, Chen YH, Yan Y, Li Q, et al. Lidocaine induces apoptosis and suppresses tumor growth in human hepatocellular carcinoma cells in vitro and in a xenograft model in vivo. *Anesthesiology*. (2017) 127(5):868-81. doi: 10.1097/01.Anes.0000500000001528

Zhang X, Pang W, Liu H, Wang J. Lidocine potentiates the cytotoxicity of 5-fluorouracil to choriocarcinoma cells by downregulating ABC transport proteins expression. *J Cell Biochem* (2019) 120(10):16533-42. doi: 10.1002/jcb.29813

Seslinski DS, Pei L, Huang Y, Fleischmann E, Marhofer P, Kurz A, et al. Recurrence of breast cancer after regional or general anesthesia: a randomised controlled trial. *Lancet*. (2019) 394(10187):1807–15. doi: 10.1016/S0140-6736(19)32313-X

Beru L, Wu Chunhua A, Sourot A, Humeau J, Xie W, Cerrato G, et al. Local anesthetics elicit immune-dependent anticancer effects. *immunotherapy Cancer*. (2022) 10(4):1-17. doi: 10.1136/ijc-2021-004151

Lirk P, Hollemann MW, Fleischer M, Weber NC, Fieg H. Lidocaine and ropivacaine, but not bupivacaine, demethylate deoxyribonucleic acid in breast cancer cells in vitro. *Br J Anaesthesia* (2014) 113 Suppl 1:i32-8. doi: 10.1093/bja/aeu201

Chen D, Yan Y, Xie J, Pan J, Chen Y, Li Q, et al. Amide-type local anesthetics may suppress tumor cell proliferation and sensitize human hepatocellular carcinoma cells to cisplatin via upregulation of RASSF1A expression and demethylation. *J Cancer*. (2020) 11(24):7312-9. doi: 10.7150/jca.66630

Gao Z, Xu Z, Hung MS, Lin YC, Wang T, Gong M, et al. Procarcine and procainacine inhibit the wnt canonical pathway by promoter demethylation of Wnt-1 in in cancer cells. *Oncol Rep* (2009) 22(6):1479-84. doi: 10.3892/or_00000590

Streemmann C, Bruclenko B, Musch T, Stopper H, Lyko F. Functional diversity of DNA methyltransferase inhibitors in human cancer cell lines. *Cancer Res* (2006) 66(5):2794-900. doi: 10.1158/0008-5472.CAN-05-2823

Lessman S, Dorsey SG. The role for epigenetic modifications in pain and analgesia response. *Nurs Res practice*. (2013) 2013:961493. doi: 10.1155/2013/961493

Lirk P, Fieg H, Weber NC, Hollmann MW. Epigenetics in the perioperative period. *Br J Pharmacol* (2015) 171(21):2748-55. doi: 10.1111/bph.12685

Caputi FP, Carbone L, Rullo L, Alessandri I, Balzani E, Melotti RM, et al. An exploratory pilot study of changes in global DNA methylation in patients undergoing major breast surgery under opioid-based general anesthesia. *Front Pharmacol* (2021) 12:735377. doi: 10.3389/fphar.2021.735377

Bezu et al. 10.3389/fonc.2022.849895
67. Zhang X, Gu G, Li X, Zhang C. Lidocaine alleviates cisplatin resistance and increases migration of MG-63/DPP cells through decreasing miR-10b. Cell Cycle (2020) 19(19):2530–7. doi: 10.1080/15384102.2020.1809914

68. Guan E, Liu H, Xu N. Lidocaine suppresses gastric cancer development through Circ_ANOS/miR-21-5p/LILR axis. Digestive Dis Sci (2022) 67(6):2244–56. doi: 10.1007/s10620-021-07035-6

69. Wen J, Li X, Deng Y, Zheng S, Xiao Y. Lidocaine inhibits glioma cell proliferation, migration and invasion by modulating the circEZL/miR-181b-5p pathway. Neuroreport. (2021) 32(1):52–60. doi: 10.1097/01.WNR.0000000000001560

70. Zhao L, Ma N, Liu G, Mao N, Chen F, Li J. Lidocaine inhibits hepatocellular carcinoma development by modulating circ_ITCU/miR-421/CPEB3 axis. Digestive Dis Sci (2021) 66(12):4834–97. doi: 10.1007/s10620-020-08678-1

71. Sun H, Sun Y. Lidocaine inhibits proliferation and metastasis of lung cancer via regulation of miR-539/EGFR axis. Artif cells nanomedicine Biotechnol (2019) 47(1):1286–74. doi: 10.1080/21691401.2019.1636807

72. Yang Q, Zhang Z, Xu H, Ma C. Lidocaine alleviates cytotoxicity-resistance in lung cancer A549/DDP cells via down-regulation of miR-21. Mol Cell Biochem (2019) 456(1-2):63–72. doi: 10.1007/s11010-018-3490-x

73. Zi H, Chen L, Ruan Q. Lidocaine represses the malignant behavior of lung carcinoma cells via the circ_PDZD8/miR-156b-5p/GOLT1A axis. Histol histopathology. (2022) 21:18423. doi: 10.14707/HH.18-423

74. Wang Y, Xie J, Liu W, Zhang R, Huang S, Xing Y. Lidocaine sensitizes the cytotoxicity of 5-fluorouracil in melanoma cells via upregulation of microRNA-493. Die Pharmazie. (2017) 72(11):663–9. doi: 10.1691/ph.2017.77616

75. Wang Z, Liu Q, Lu J, Cao J, Wang XY, Chen Y. Lidocaine promotes autophagy of SH-SYSY cells through inhibiting PI3K/AKT/mTOR pathway by upregulating miR-145. Tisscell Res (2020) 9(4):467–73. doi: 10.1093/tiss/taa049

76. Zhang Y, Liu L, Xue P, Wang L. Long noncoding RNA LINC01347 modulated lidocaine-induced cytotoxicity in SH-SYSY cells by interacting with hsa-miR-145-3p. Neurotox Res (2021) 39(5):1440–8. doi: 10.1007/s12640-021-00363-9

77. Xia W, Wang L, Yu D, Mu X, Zhou X. Lidocaine inhibits the progression of retinoblasoma in vitro and in vivo by modulating the miR20a/miR-EGFR axis. Mol Med Rep (2019) 20(2):1333–42. doi: 10.3892/mmr.2019.10365

78. Zhao L, Han S, Hou J, Shi W, Zhao Y, Chen Y. The local anesthetic ropivacaine promotes progression of breast cancer by regulating miR-27b-3p/YAP axis. Aging. (2021) 13(2):16341–52. doi: 10.18632/aging.203160

79. Chen X, Liu W, Guo X, Huang S, Song X. Ropivacaine inhibits cervical cancer cell growth via suppression of the miR96/MEG2/pSTAT3 axis. Oncol Rep (2020) 43(5):1659–68. doi: 10.3892/or.2020.7521

80. Lu Y, Yang C, Zhang L, Ding J. Ropivacaine retards the visibility, migration, and invasion of choriocarcinoma cells by regulating the long noncoding RNA OGERP1/MicroRNA-4731-3p/HEF3A axis. Mol Biotechnol (2022) 64(5):499–509. doi: 10.1007/s12053-021-00429-1

81. Zhang N, Xing X, Gu F, Zhou G, Liu X, Li B. Ropivacaine inhibits the growth, migration and invasion of glioblastoma cells by regulating the long noncoding RNA PGC-1alpha transcriptional complex. Nature. (2007) 450(7178):734–40. doi: 10.1038/nature06322

82. Gong X, Dan J, Li F, Wang L. Suppression of mitochondrial respiration with local anesthetic ropivacaine targets breast cancer cells. J Thoracic. (2018) 10(3):2798–20. doi: 10.21037/jtd.2018.05.21

83. Deng Z, Zan Y, Cai H. Ropivacaine suppresses the proliferation, invasion, and migration of glioblastoma via modulating the miRNA-21-5p/KAT8 regulatory NSL complex subunit 2 axis. Bioengineered. (2022) 13(3):5975–86. doi: 10.1080/21659797.2022.2037955

84. Cunningham JT, Rodgers JT, Arlow DH, Vazquez F, Mootha VK, Puigserver F. miTOR controls mitochondrial oxidative function through a YY1-PGC-1alpha transcriptional complex. Nature. (2007) 450(7178):734–40. doi: 10.1038/nature06322

85. Kwon SY, Sheu A, Song CQ, Zhang XO, Jiang T, Dang H, et al. Depletion of TRRAP induces p53-independent senescence in liver cancer by down-regulating mitotic gene. Hepatology. (2020) 71(1):275–90. doi: 10.1002/hep.30807

86. Liang DY, Li X, Clark JD. Epigenetic regulation of opioid-induced hyperalgesia, dependence, and tolerance in mice. J pain. (2013) 14(1):36–47. doi: 10.1016/j.jpain.2012.10.005

87. Cheng JC, Matson CB, Gonzales FA, Ye W, Greer S, Marquez VE, et al. Inhibition of DNA methylation and reactivation of silenced genes by zebralinarin. J Natl Cancer Institute. (2005) 97(5):399–409. doi: 10.1093/jnci/djg539.5.399

88. Cheng JC, Weisenberger DJ, Gonzales FA, Liang G, Xu GL, Hu YG, et al. Continuous zebralinarin treatment effectively sustains demethylation in human bladder cancer cells. Mol Cell Biol (2004) 24(3):1270–8. doi: 10.1128/MCB.24.3.1270-1278.2004

89. Fang MZ, Wang Y, Ai N, Hou Z, Sun Y, Liu H, et al. Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation silenced genes in cancer cell lines. Cancer Res (2003) 63(23):7563–70.

90. Liu Z, Xie Z, Jones W, Pavlovic RE, Liu S, Yu J, et al. Curcumin is a potent DNA hypomethylating agent. Bioorganic medicinal Chem Letters. (2009) 19(3):706–9. doi: 10.1016/j.bmcl.2008.12.041

91. Schneeiberger Y, Stenzig J, Huebner F, Schaefer A, Reichenspurner H, Eschenhagen T. Pharmacokinetics of the experimental non-nucleosidic DNA methyltransferase inhibitor n-Phthalyl-L-Tryptophan (RG 108) in rats. Basic Clin Pharmacol toxicology. (2016) 118(5):327–32. doi: 10.1111/bcpt.12514

92. Yoon JR, Whipple RA, Balzer EM, Cho EH, Matrone MA, Peckham M, et al. Local anesthetic bupivacaine through multiple mechanisms independent of sodium channel blockade. Breast Cancer Res Treat (2011) 129(3):691–701. doi: 10.1007/s10549-010-1239-7

93. Dan J, Gong X, Li D, Zhu G, Wang L, Li F. Inhibition of gastric cancer by local anesthetic bupivacaine through multiple mechanisms independent of sodium channel blockade. BioMedicine pharmacotheraphy = Biomedicines pharmacotheraphy. (2018) 103:823–89. doi: 10.1016/j.biot.2018.04.106

94. Tabak P, Masroui S, Graylow KR, Zarei M, Esmailpoor ZH. Targeting miRNAs with anesthetics in cancer: Current understanding and future perspectives. Biomedicines pharmacotheraphy = Biomedicines pharmacotheraphy. (2021) 144:112309. doi: 10.1016/j.biot.2021.112309